1. Home
  2. EXAS vs ENSG Comparison

EXAS vs ENSG Comparison

Compare EXAS & ENSG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

HOLD

Current Price

$101.54

Market Cap

11.0B

Sector

Health Care

ML Signal

HOLD

Logo The Ensign Group Inc.

ENSG

The Ensign Group Inc.

HOLD

Current Price

$175.79

Market Cap

10.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXAS
ENSG
Founded
1995
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Hospital/Nursing Management
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.0B
10.5B
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
EXAS
ENSG
Price
$101.54
$175.79
Analyst Decision
Buy
Buy
Analyst Count
20
5
Target Price
$77.94
$196.40
AVG Volume (30 Days)
10.8M
319.3K
Earning Date
11-03-2025
11-03-2025
Dividend Yield
N/A
0.14%
EPS Growth
N/A
35.03
EPS
N/A
5.59
Revenue
$3,082,033,000.00
$4,829,467,000.00
Revenue This Year
$19.40
$21.00
Revenue Next Year
$13.51
$12.30
P/E Ratio
N/A
$31.10
Revenue Growth
14.47
17.55
52 Week Low
$38.81
$118.73
52 Week High
$101.95
$194.00

Technical Indicators

Market Signals
Indicator
EXAS
ENSG
Relative Strength Index (RSI) 89.64 43.79
Support Level $100.95 $170.49
Resistance Level $101.95 $179.73
Average True Range (ATR) 0.34 4.24
MACD -0.87 -0.97
Stochastic Oscillator 59.71 27.25

Price Performance

Historical Comparison
EXAS
ENSG

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

About ENSG The Ensign Group Inc.

Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.

Share on Social Networks: